JP Morgan Chase
JSPR icon

JP Morgan Chase’s Jasper Therapeutics JSPR Stock Holding History

JP Morgan Chase’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Hold
9
– – ﹤0.01% 7677
2026
Q1 		$8 Hold
9
– – ﹤0.01% 7444
2025
Q4 		$16 Sell
9
-200
-96% -$401 ﹤0.01% 7315
2025
Q3 		$497 Sell
209
-64,879
-100% -$197K ﹤0.01% 7052
2025
Q2 		$361K Buy
65,088
+59,547
+1,075% +$293K ﹤0.01% 4938
2025
Q1 		$23.8K Buy
5,541
+376
+7% +$2.5K ﹤0.01% 6102
2024
Q4 		$110K Sell
5,165
-11,226
-68% -$234K ﹤0.01% 5718
2024
Q3 		$308K Buy
16,391
+11,567
+240% +$230K ﹤0.01% 5191
2024
Q2 		$110K Buy
+4,824
New +$116K ﹤0.01% 5467

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's JSPR Position: Q2 2026 in Review

JP Morgan Chase held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 9 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #7677.

JP Morgan Chase first reported a position in JSPR in Q2 2024 and has held it in 9 quarters since. The position peaked at $361K in Q2 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • JP Morgan Chase held 9 shares of Jasper Therapeutics worth $4 as of Q2 2026.
  • JP Morgan Chase left its Jasper Therapeutics share count unchanged in Q2 2026.
  • Jasper Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7677 holding.
  • JP Morgan Chase first reported a position in Jasper Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • JP Morgan Chase's Jasper Therapeutics position peaked at $361K in Q2 2025.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.